highly significantp < 0.0001
When other therapies were analyzed together with GLP-1 RA (model 5), patients treated with GLP-1 RA had a 32.7 unit greater reduction in CAP compared to those not on these agents, a highly significant (t = 9.9, p < 0.0001), with a positive and robust effect size (partial correlation 0.5).